5. FDA approves KEYTRUDA (Pembrolizumab) for treatment of patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment, then continued as single agent as adjuvant treatment after surgery. News release. Merck. July 27, 2021. Accessed May ...
5. FDA approves KEYTRUDA (Pembrolizumab) for treatment of patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment, then continued as single agent as adjuvant treatment after surgery. News release. Merck. July 27, 2021. Accessed May ...
Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Annals of Oncology, 2020.2. Nanda Rita, Liu Minetta C, Yau Christina et al. Effect of Pembrolizumab Plus ...
238MO PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohortdoi:10.1016/j.annonc.2024.08.181F. CherifiL. CabelC. BousrihE. VolantF. DalencB. MeryM. Auvray KuentzM. AlexandreL. BenistantM. Leheurteur...
Trial Registration ClinicalTrials.gov Identifier: NCT03036488 Introduction Triple-negative breast cancer (TNBC) has a poor prognosis and is recognized as the most difficult-to-treat breast cancer subtype.1,2 Neoadjuvant chemotherapy is standard-of-care treatment for early TNBC.3-5 The sho...
adjuvant pembrolizumab post-surgery has extended event-free survival (EFS) compared to neoadjuvant chemotherapy alone in patients with early triple-negative breast cancer (TNBC) [2], immunochemotherapy including pembrolizumab has become the standard of care for managing early TNBC patients at high risk...
1.Nanda R, Chow LQ, Dees EC, et al: Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol. May 2, 2016 (early release online). Anti–PD-1 Treatment With Pembrolizumab in Gastric/Gastroesophageal Junction Cancers: Who Is...
These are not all the possible side effects of KEYTRUDA. Talk to your health care provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visitwww.fda.gov/medwatchor call1-800-FDA-1088. ...
Officials with the FDA have approved pembrolizumab (Keytruda; Merck), an anti-PD-1 therapy, in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (Combined Positive Score [CPS]...
A pivotal study of pembrolizumab (Keytruda, Merck) in combination with chemotherapy has shown statistically significant improvements in event-free survival (EFS) among patients with high-risk, early-stage triple-negative breast cancer (TNBC), according to a press...